Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis | Synapse
April 15, 2026
Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis
Key Points
To evaluate the effectiveness of various antihyperglycemic therapies in preventing liver-specific events in patients with type 2 diabetes.
Conducted a network meta-analysis of randomized trials
Assessed different antihyperglycemic drug classes
Compared liver-specific risk reduction across therapies
Found that liver risk reduction varies significantly among antihyperglycemic drug classes
Indicated the need for further randomized trials to verify drug effects
Abstract
Liver-specific risk reduction is not uniform across antihyperglycemic drug classes. Randomized trials are needed to determine whether these associations reflect true drug effects.